Latest Regulatory Progress News

Uscom Limited reported a 25% revenue decline in FY25 amid global geopolitical challenges but reinforced its commitment to growth through strategic partnerships and innovative medical technologies.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.

Right Resources has confirmed extensive high-grade gold mineralisation along a 1km strike at its Pilot Project in New South Wales, with maiden drilling now in progress to validate these promising findings.

Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.

Lake Resources N.L. reports significant progress on its Kachi lithium project, unveiling enhanced project economics and next-generation lithium extraction technology amid a bullish lithium market and supportive Argentine political climate.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Geopacific Resources has extended the Woodlark Gold Project Definitive Feasibility Study to Q1 2026, aiming to integrate optimisation and de-risking measures amid a gold price surge and promising drilling results.

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.

Clover Corporation delivered a robust FY25 with strong second-half sales and operational milestones, positioning itself for continued growth in FY26 amid ongoing innovation and market expansion.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.

Australian Bond Exchange narrowed its FY25 loss by 26% through disciplined cost cuts and is advancing its fintech strategy with AI-driven credit tools and tokenised asset ambitions.